What's Happening?
A recent study has identified Solriamfetol, a drug sold under the brand name Sunosi, as an effective treatment for fatigue among early-morning workers. Conducted by Dr. Charles A. Czeisler and his team at Mass General Brigham, the study focused on individuals
who start work between 3 a.m. and 7 a.m., a group previously overlooked in clinical trials. These workers often experience fatigue due to waking up at their body's biological low point, which can lead to increased risks of cardiovascular disease, road accidents, and chronic fatigue. The study involved 78 participants who were given either Solriamfetol or a placebo over four weeks. Results showed that those taking Solriamfetol stayed awake an average of 12.5 minutes longer than before treatment, compared to a 3.1-minute improvement in the placebo group. This significant difference highlights the drug's potential to improve alertness and performance during early shifts.
Why It's Important?
The findings of this study are significant as they provide a scientifically backed treatment option for early-morning workers, a demographic that includes essential personnel such as bakers, drivers, and hospital staff. These workers often face unique challenges due to their schedules, which can impact their health and safety. By offering a viable solution to combat fatigue, Solriamfetol could enhance workplace safety and productivity, reduce health risks, and improve the quality of life for these individuals. The study's results also pave the way for further research and potential formal approval of Solriamfetol for shift work disorder, marking a significant advancement in occupational health.
What's Next?
Following the success of this trial, researchers plan to conduct a follow-up study involving overnight workers to further explore Solriamfetol's efficacy in treating shift work disorder. This could lead to the drug being formally approved for this condition, making it the first medication specifically labeled for shift work disorder. Such approval would provide healthcare professionals with a reliable treatment option for managing fatigue in shift workers, potentially influencing workplace policies and health guidelines.
